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Abstract Hantaan virus (HTNV) is the type of Hantavirus
causing hemorrhagic fever with renal syndrome, for which no
specific therapeutics are available so far. Cell type-specific
internalizing antibodies can be used to deliver therapeutics
intracellularly to target cell and thus, have potential applica-
tion in anti-HTNVinfection. To achieve intracellular delivery
of therapeutics, it is necessary to obtain antibodies that
demonstratesufficientcelltype-specificbinding,internalizing,
and desired cellular trafficking. Here, we describe the
prokaryotic expression, affinity purification, and functional
testing of a single-chain Fv antibody fragment (scFv) against
HTNVenvelop glycoprotein (GP), an HTNV-specific antigen
normally located on the membranes of HTNV-infected cells.
This HTNV GP-targeting antibody, scFv3G1, was produced
in the cytoplasm of Escherichia coli cells as a soluble protein
and was purified by immobilized metal affinity chromato-
graphy. The purified scFv possessed a high specific antigen-
binding activity to HTNV GP and HTNV-infected Vero E6
cells and could be internalized into HTNV-infected cells
probablythroughtheclathrin-dependentendocytosispathways
similar to that observed with transferrin. Our results showed
that the E. coli-produced scFv had potential applications in
targeted and intracellular delivery of therapeutics against
HTNV infections.
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Introduction
Hantaviruses, which belong to the family of Bunyaviridae,
are composed of a spherical lipid envelop, four viral
proteins, and three single-stranded negative-sensed RNA
segments (Schmaljohn and Dalrymple 1983). While the
small (S [∼2.0 kb]) and medium segments (M [∼3.6 kb])
encode the nucleocapsid protein (NP) and the two envelop
glycoproteins (GPs) G1 and G2, respectively, the large
segment (L [∼6.0 kb]) contains the coding sequence for the
viral RNA polymerase (Plyusnin et al. 1996). Hantaviruses
can infect humans when virus-contaminated excreta from
persistently but asymptomatically infected rodents are
inhaled (Schmaljohn and Hjelle 1997). Within the genus
Hantavirus, two groups have been identified: New World
and Old World Hantaviruses. They not only differ in their
geographical distribution buta l s ov a r yr e g a r d i n gt h e
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such as Hantaan, Seoul, Dobrava, and Puumala viruses
(Schmaljohn and Hjelle 1997; Sjölander et al. 2002), cause
hemorrhagic fever with renal syndrome (HFRS), whereas,
New World Hantaviruses, such as Sin Nombre and Andes
viruses (Schmaljohn and Hjelle 1997; Meyer and Schmaljohn
2000), are the causative pathogen of Hantavirus pulmonary
syndrome (HPS). HFRS is characterized by fever, renal
failure, thrombocytopenia, and in severe cases hemorrhagic
manifestations with a mortality rate of 2–10% (Peters et al.
1999), while HPS is featured by severe acute respiratory
dysfunction and a mortality rate of approximately 50%
( N i c h o le ta l .1993; López et al. 1996). More than 100,000
cases of HFRS occur annually worldwide and most are
documented in China (Song 1999). Hantaan virus (HTNV),
the prototype of the Hantavirus genus, is responsible for
numerous cases of HFRS. The antiviral drug ribavirin, which is
mainly effective in the early phase of HFRS, is currently under
clinical investigation but has not been proven to be sufficient to
prevent Hantavirus propagation. Instead, the treatment is
restricted to supportive procedures to keep life-threatening
symptoms under control (Linderholm and Elgh 2001).
Suppression of pathogenic genes via nucleic acid-based
reagents holds great promises as novel therapeutic approach
against a wide variety of diseases, including infectious
diseases, cancer, and genetic disorders. In this regard,
antisense oligonucleotides and more recently, small inter-
fering RNAs have also been used (Corey 2007; Dorsett and
Tuschl 2004). However,amajorchallengeto thedevelopment
of therapeutic nucleic acid drugs is specific and efficient in
vivo delivery to target cells. To enhance the therapeutic
efficiency, delivery of these innovative therapeutic agents into
the cytosol of target cells is required. Recent studies suggest
that specific gene silencing in vivo can be achieved by
combining these nucleic acid-based reagents with cell type-
specific internalizing antibodies. The antibody-directed thera-
peuticcomplexenterstargetcellsthroughreceptorendocytosis
and is subsequently released into the cytosol to specifically
silence target gene expression. Antibody fragments fused with
a small nucleic acid-binding protein and antibody fragment-
directed nanoimmunoliposomes are two examples of effective
delivery vehicles in vivo (Liu 2007).
To achieve targeted and intracellular delivery of thera-
peutic genes, antibodies with well-defined cell type-specific
binding and internalizing capacity are required. Recombinant
antibody technology now allows researchers to engineer low-
cost antibodies with specificity and high binding affinity.
Single-chainFvantibodyfragments(scFv)arepolypeptidesin
which the variable domains of immunoglobulin heavy (VH)
and light (VL) chain can be connected via a flexible
polypeptide linker (Bird et al. 1988). As a delivery vehicle
of therapeutic agents, scFv antibody offers several advan-
tages over monoclonal antibody (MAb), e.g., efficient tissue
penetration due to their reduced size (∼30 kDa). Small
recombinant antibodies can be expressed in Escherichia coli,
providing an economic and simple method for large-scale
production. Binding affinity and internalization of recombi-
nant antibodies can be improved by mutagenesis in
complementarity-determining regions (CDRs) and selection
via phage display (Jackson et al. 1995;Y a n ge ta l .1995;
Schier et al. 1996) and fusion to protein transduction domain
(Joliot and Prochiantz 2004;L i n d g r e ne ta l .2000). Therefore,
scFvs provide useful tool for targeted and intracellular
delivery of therapeutically effective molecules.
Hantavirus envelop GPs are transmembrane proteins,
which are normally located on the surface of virus-infected
cells (Ogino et al. 2004). Thus, they become a suitable
target for antibody-mediated delivery of therapeutics. In this
study, the generation of a soluble recombinant HTNV GP
antibody, scFv3G1, derived from hybridoma cells and the
purification of bacterially expressed scFv3G1 were described,
and the cell type-specific binding and internalizing properties
of this single-chain antibody were evaluated.
Materials and methods
Cells
The Africangreenmonkeykidneyepithelial cell-derivedVero
E6 cell line (Vero C1008, ATCC CRL 1586) was cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Gibro-BRL),
supplementedwith 10% heatedinactivatedfetal bovineserum
(FBS) in a 5% CO2 humidified incubator.
Hybridoma cell line (clone 3G1) and hybridomas
producing anti-HTNV GP monoclonal antibody (MAb3G1)
were provided by Dr. ZK Xu (Luo et al. 2003; Hu et al.
2005). The mouse hybridoma cell line 3G1 was propagated
for scFv construction.
Single-chain Fv antibody fragment construction
Total RNA was isolated from about 10
7 freshly subcloned
hybridoma 3G1 cells using Trizol Reagent (Gibco). The
first-strand cDNA was synthesized from total RNA using
SuperScript™ II Reverse Transcriptase and oligo (dT)
primer (Invitrogen) according to the manufacturer’sp r o t o c o l .
cDNAs encoding the antibody variable domains (VH and VL)
were amplified by separate polymerase chain reaction (PCR)
under standard conditions, performed for 30 cycles, using
Taq DNA polymerase (Invitrogen) in a thermocycler (Perkin
Elmer, PE2400). The VH coding regions were amplified with
primers VHRev and VHFor, while the VL fragments were
obtained by PCR using primers VLRev and VLFor. Primers
sequences are listed in Table 1. The amplified DNAs were
cloned into the pGEM-T vector (Promega). The constructs
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sequences and deduced amine acid sequences was performed
using the GenBank database and Kabat database (http://www.
antibodyresource.com/antibody-database), respectively.
A synthetic gene encoding scFv3G1 was amplified by
“splice-overlapped extension” (Horton et al. 1989). The genes
encoding the variable domains were independently modified
in an initial PCR amplification using primers VHRevEcoRI
and VHLinkFor for the VH fragment and VLLinkRev and
VLForSalI for the VL domain (Table 1). VHLinkFor and
VLLinkRev carry overlapping sequences encoding the link
peptide (Gly4Ser)3, while VHRevEcoRI and VLForSalI
introduce EcoRI and SalI restriction sites at the upstream
and downstream ends of the PCR product, respectively. This
allows cloning of the amplified fragment into the
corresponding sites of pET32a vector (Novagen), a prokary-
otic expression vector harboring a thioredoxin gene and two
groups of polyhistidine sequences to facilitate disulfide bond
formation, solubility, and purification of recombinant proteins.
Recombinant scFv antibody expression and purification
A single clone pET32a-scFv3G1 was used to transform fresh
competent E. coli BL21 (DE3) strain. Colonies were grown in
LB medium supplemented with 100 μg/mL ampicillin at 37°C
until OD600 reaches approximately 0.4–0.6. Then, bacteria
were induced for production of scFv3G1 with 0.2 mM IPTG,
and the temperature was shifted to 30°C for 3 h. Bacteria from
cultures were centrifuged, and the cytoplasm was extracted
after sonication. The recombinant protein scFv3G1 was
purified using the His-Bind purification kit (Novagen) accord-
ing to the manufacturer’s instructions. Fractions containing the
recombinant protein were pooled, concentrated by ultrafiltra-
tion (Millipore Corp.), and stored at −20°C until use. The
protein concentration was determined using the BCA assay kit
(Pierce) with bovine serum albumin (BSA) as a standard.
SDS-PAGE and Western blot analysis
Proteins were separated on 15% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) gels using
Mini-Protein 3 system (Bio-Rad Laboratories) according to
the manufacturer’s instructions. Samples were mixed with
an equal volume of 2× Laemmli buffer (S3401, Sigma-
Aldrich) and heated at 95°C for 5 min. The sample of
15 μL protein (or cell lysate) or 10 μL low molecular
weight protein marker (Pharmacia) was loaded per lane.
The gels were run at 60 mA for 45 min, and resolved protein
samples were visualized by staining with Coomassie brilliant
blue R-250 (Sigma-Aldrich). The crude cytoplasmic prepara-
tion and the purified protein were transferred to a polyviny-
lidene difluoride membrane (PVDF; Amersham Biosciences)
using semidry Western blot transfer apparatus (Bio-Rad
Laboratories). The membranes were blocked with 3% BSA
(Sigma-Aldrich) in PBS supplemented with 0.05% [v/v]
Tween-20 (PBST) for 1 h at room temperature, then washed
five times with PBST, and incubated with mouse anti-His-
Tag antibody as a primary antibody (Qiagen) at 1:3,000
dilution overnight at 4°C. Then the membranes were washed
again and incubated with HRP-conjugated goat anti-mouse
IgG as a second antibody (Abcam) at 1:3,000 dilution in
PBST at room temperature for 90 min. After washing with
PBST, the reaction product was visualized with enhanced
chemiluminescence (Amersham) for 5–10 min at room
temperature in the dark. For analysis of immunoreactivity
of scFv3G1, HTNV GP or unrelated Hantavirus nucleocapsid
protein (HTNV NP) was transferred to a PVDF membrane,
incubated with scFv3G1 at 100 nM overnight at 4°C, and
followed by incubation with either HRP-conjugated anti-His-
Tag antibody (Abcam) or HRP-conjugated goat anti-mouse
IgG. MAb3G1 was used as positive control while HBsAg-
specific scFv15 antibody acted as negative control (Wen et
al. 2007a, b).
Indirect ELISA
Polystyrene plates (96 wells; Nalge Nunc) were coated
overnight at 4°C with HTNV GP or unrelated HTNV NP
antigen at 1:10 dilution in 100 µL 0.1 M carbonate–
bicarbonate buffer (pH 9.6). After three washes with PBST,
the wells were blocked with 200 µL of 1% BSA in PBST
for 1 h at room temperature and washed as above. The
Table 1 List of primers used for the generation of synthetic genes encoding scFv3G1
VHRev (GC)AGGC(GC)CAGCTGCAG(GC)AGTC(AT)GG
VHFor GGTCCCTTGGCCCC
VLRev GACATT(GC)(AT)G(AT)TGAC(GC)CAGTCTCC
VLFor ACGTTTGATCTCGAGCTTGGTCCC
VHRevEcoRI TTTGAATTCGAGGCGCAGCTGCAGGAGTC
VHLinkFor TCCGCCTGAACCGCCTCCACCTGAGGAGACGGTGACCGTGGTCCC
VLLinkRev GGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGGACATTGTGATGACGCAGTCT
VLForSalI TTTGTCGACACGTTTGATCTCGAGCT
Restriction sites EcoRI and SalI used for cloning the scFv are underlined
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HBsAg-specific scFv15 twofold serially diluted in PBST
from 1,000 to 0.1 nM. The plates were incubated with
primary antibody solutions overnight at 4°C. The wells
were washed again, and the bound antibodies were detected
using either HRP-conjugated anti-His-Tag antibody or
HRP-conjugated goat anti-mouse IgG in PBST at room
temperature for 90 min. After final washing, 100 µL of
substrate solution composed of 4 mg o-phenylenediamine
(Sigma-Aldrich) in 10 mL of 0.1 M citrate–phosphate
buffer (pH 5.0) containing 0.01% H2O2 was added to each
well. The color reactionwas developed inthe darkfor 15min,
and absorbance at 450 nm was determined using Tecan
GENios microplate reader. Assay results are expressed as the
means±SD of three independent experiments.
Preparation of infected cells
Cultures of Vero E6 cells were inoculated with HTNV strain
76–118 at a MOI of 0.5 in serum-free medium. After
incubation for 1 h at 37°C, unbound viruses were removed
by a triple washing. Maintenance medium (DMEM with 2%
FBS) was added to the cells and changed every 5 days. The
cells were ready for further use 10 days after inoculation.
Biosafety level 3 facilities were used throughout these
experiments for Hantavirus cultivation.
Flow cytometry
Flow cytometric analysis was used to evaluate whether
scFv3G1 can bind HTNV GP expressed on the cell
membrane. The 10-day infected Vero E6 cells or uninfected
cells were washed, scraped, and incubated with the
recombinant scFv3G1 at 100 nM in PBST at 4°C for
30 min. In parallel experiments, MAb3G1 was used as
positive control, while HBsAg-specific scFv15 antibody
acted as negative control. Cells were washed again and
stained with fluorescein isothiocyanate (FITC)-conjugated
anti-His-Tag antibody (Abcam) or FITC-conjugated goat
anti-mouse IgG antibody (Santa Cruz Biotechnology) at
1:1,000 dilution in PBST at 4°C. After 30 min of staining,
the cells were washed a third time and then analyzed by
flow cytometry using a FACSCalibur (Becton Dickinson)
instrument.
Immunofluorescence staining
The immunofluorescence staining was performed to deter-
mine whether the scFv3G1 can be internalized into HTNV-
infected cells. The Vero E6 cells infected with HTNV for
10 days were seeded on 24-well coverslips at 3×10
4cells
per well and grown in DMEM (2% FBS) at 37°C in 5%
CO2 incubator overnight. The cells were washed three
times in PBS and incubated with FITC-tagged scFv3G1,
FITC-tagged MAb3G1, or together with Texas red-tagged
transferrin (Molecular Probes) for 30 min at 37°C. Then,
cells were washed and fixed in 3% paraformaldehyde for
5 min, followed by DAPI counterstaining for nuclei. After
being washed with PBS, the coverslips were mounted on
slides with ProLong Gold antifade reagent (Molecular
Probes) and observed with a laser scanning confocal
microscope (Olympus FV-1000).
Accession numbers
The nucleotide sequence for VH domains of the MAb3G1 is
deposited at GenBank as FJ751231 and that for VL domains
of the MAb3G1 as FJ751232.
Results
Cloning of the scFv3G1 coding sequence
In order to investigate the cell type-specific binding and
internalizing properties by HTNV-infected cells, coding
sequences of VH and VL domains of the MAb3G1 were
cloned initially from the parental hybridoma cell line and
sequenced. The deduced amino acid sequences were
compared with those of variable regions of immunoglobulins
stored in the immunological Kabat database. The three loops
corresponding to the CDRs of the VH and VL regions and the
amino acid residues involved in the canonical structures were
identified. The cDNA sequences of VH and VL are submitted
to the GenBank database (accession number FJ751231 and
FJ751232). The cDNAs encoding for MAb3G1 VH and VL
were fused by splice-overlapped extension. PCR amplifica-
tion using primers VHRevEcoRI and VLForSalI generated a
0.7-kb fragment (Fig. 1a). This PCR fragment was inserted
between EcoRI/SalI cloning site in the pET32a vector and
sequenced. Nucleotide and deduced amino acid sequences of
scFv3G1 are shown in Fig. 1b.
Production and purification of the scFv3G1
The recombinant protein was expressed by E. coli BL21
(DE3) strain transformed with pET32a-scFv3G1. Briefly,
transformed BL21 cells were grown in LB medium at 37°C
and incubated with 0.2 mM IPTG at 30°C for 3 h.
Cytoplasmic recombinant protein, containing a thioredoxin
(11 kDa) at the N terminus and two group of polyhistidines,
was extracted after sonication. Immobilized metal affinity
purification of scFv3G1 was carried out using Ni-NTA
His•Bind Resin that specifically binds the polyhistidine.
Eluted fractions were collected and concentrated by
ultrafiltration.
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purified recombinant protein showed a prominent band at
the predicted size for scFv3G1 fusion protein molecular
weight of about 46 kDa (Fig. 2a), which was detected in all
fractions from induced bacteria culture. This His-tagged
protein was further examined by Western blot using anti-
His-Tag antibody (Fig. 2b). These results showed that this
recombinant scFv3G1 protein was released into cytoplasm
as a soluble protein, and no degradation products were
revealed, suggesting the high solubility and stability of the
recombinant protein. The average concentration of affinity-
purified protein was 1 mg/mL. In total, about 8 mg of
soluble recombinant protein scFv3G1 with more than 90%
purity was obtained per 1 L of E. coli culture.
scFv3G1 specifically recognizes target antigen and retains
the antigen-binding activity
In order to investigate the antigen-specific binding of the
recombinant scFv3G1, a solid-phase assay was performed
using coated plates with HTNV GP as a target antigen.
Within the rang tested, increased concentrations of
scFv3G1 corresponded to enhanced colorimetric signals,
while no significant background was detected in wells
coated with the control HTNV NP antigen (Fig. 3a).
Moreover, the scFv3G1 showed clear reactivity similar to
the parental MAb3G1 (Fig. 3b). The observed difference in
binding presumably shows reduced avidity of scFv, based
Fig. 1 Construction of HTNV
GPs targeting scFv3G1. a PCR
for the construction of scFv
antibody-encoding gene. The
genes encoding the variable
heavy chain (VH) and variable
light chain (VL) fragments were
amplified and assembled via a
short nucleotide linker in a
VH-linker-VL format. The
amplified products were
resolved in 1.5% agarose gel
and stained with ethidium
bromide. DNA markers are
given in base pairs indicated at
the left. b Nucleotide and
deduced amino acid sequences
of scFv3G1. The linker
fragment (Gly4Ser)3 is shown in
italics. The complementarity-
determining regions (CDRs) of
the VH (H-CDR) and VL
(L-CDR) domains are
underlined, and the sequences
were identical to those reported
in the Kabat database. The
four conserved Cys are
indicated by stars
Fig. 2 Expression and purification analysis. Escherichia coli BL21
(DE3) was transformed with the pET32a-scFv3G1 construct. After
induction, cytoplasmic proteins were extracted following sonication.
Cytoplasmic fraction was purified by immobilized metal affinity
chromatography. Bacterial cytoplasmic extract and purified recombi-
nant scFv3G1 antibody were subjected to 15% SDS-PAGE, stained
with Coomassie brilliant blue (a) or transferred to PVDF membrane
for Western blot analysis using anti-His-Tag antibody (b). c Western
blot analysis of immunoreactivity of scFv3G1. HTNV GP or unrelated
HTNV NP was transferred to PVDF membrane, incubated with
scFv3G1, and followed by incubation with HRP-conjugated anti-His-
Tag antibody. Molecular weight markers are given in kilodaltons
indicated on the left
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antigen recognition surface, while scFv3G1 retains only
one. We assayed the immunoreactivity of scFv3G1 by
Western blot and found that scFv3G1 detected a polypeptide
band of about 56 kDa corresponding to HTNV glycoprotein
G2 molecular weight similar to that observed with MAb3G1,
while no staining background was detected with unrelated
HTNV NP antigen and when irrelevant control HBsAg-
specific scFv15 was used instead of scFv3G1 (Fig. 2c). To
evaluate whether the scFv3G1 was able to bind HTNV GP
on the cell membrane, Vero E6 cells infected with HTNV for
10 days were incubated with the purified scFv3G1 and
examined by flow cytometry. This scFv bound with HTNV
GP expressed on the membrane of HTNV-infected cells
similar to that observed with MAb3G1 (Fig. 3c), while
scFv3G1 did not react with uninfected cells, and several
other cell lines (data not shown) and control HBsAg-specific
scFv15 did not react with HTNV-infected cells in parallel
experiments (Fig. 3c). These results indicate that this
recombinant scFv3G1 possesses biological activity of HTNV
GP-specific binding.
scFv3G1 can be internalized into cytoplasm
of HTNV-infected cells
Since intracellular delivery requires a cell type-specific
internalizing antibody, we analyzed whether this scFv can be
internalized into infected cells. Vero E6 cells preinfected with
HTNV were incubated with FITC-tagged scFv3G1 antibody
or FITC-tagged MAb3G1 for 30 min. As shown in Fig. 4a,
specific fluorescence was observed both on the membrane
and in the cytoplasm of HTNV-infected cells. This fluores-
cence diffusion pattern indicates that both the scFv3G1 and
the parental MAb3G1 can be efficiently internalized into the
cytoplasm following binding to its target antigen HTNV GP
on the surface of HTNV-infected cells.
Fig. 3 HTNV GP antigen-specific binding characteristics of
scFv3G1. a Solid-phase binding of purified scFv3G1 to HTNV GP
antigen as measured by ELISA. The wells were coated with HTNV
GP or HTNV NP and then incubated with purified twofold serially
diluted scFv3G1 from 1,000 to 0.1 nM. b To compare the HTNV GP-
specific antigen-binding activity of scFv3G1 to that of MAb3G1,
serially diluted scFv3G1 and MAb3G1 were assayed. Results are
plotted as percentages of HTNV GP binding. c Flow cytometric
analysis to evaluate whether scFv3G1 can bind HTNV GP antigen
expressed on the cell membrane. Ten-day HTNV-infected Vero E6
cells or uninfected cells were incubated with 100 nM purified
scFv3G1 and followed by detection with FITC-conjugated anti-His-
Tag antibody
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endocytotic pathway
To further investigate the internalizing pathway of this
scFv, Vero E6 cells preinfected with HTNV were incubated
with FITC-tagged scFv3G1 and Texas red-tagged transfer-
rin, as an indicator of clathrin-dependent endocytosis. As
shown in Fig. 4b, merged staining of scFv3G1 and
transferrin revealed a colocalization of the recombinant
antibody with clathrin-coated endocytic vesicles. Thus, the
internalization of scFv3G1 is likely achieved through
clathrin-dependent endocytosis. Taken together, these
results suggest that the recombinant single-chain antibody,
scFv3G1, possesses the HTNV GP-specific binding activity,
and subsequent internalization through receptor endocytosis
may allow targeted and intracellular delivery of therapeutics
against HTNV infection.
Discussion
Hantaviruses are enveloped, negative-sense RNA viruses,
which can cause human infection after inhalation of
aerosols (feces, saliva, and urine) from rodent hosts, and
Fig. 4 Internalization of
scFv3G1. Vero E6 cells infected
with HTNV for 10 days were
incubated with FITC-labeled
scFv3G1 or FITC-labeled
MAb3G1 in the absence (a) and
in the presence (b) of Texas
red-labeled transferrin as an
indicator of clathrin-dependent
endocytosis at 37°C for 30 min
to allow internalization. Nuclei
were counterstained with DAPI.
Immunofluorescence was
observed under confocal
microscopy. The colocalization
of the scFv3G1 antibody with
clathrin-coated endocytic
vesicles are indicated by arrows.
Scale bar 20 μm
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Although Hantaviruses have been known to infect humans
for almost a century, no specific therapeutics are available
for the treatment of HFRS and HPS. Recent studies suggest
that cell type-specific internalizing antibodies delivery of
therapeutic genes is potentially a powerful strategy, given
that a direct attack of the infected cells results in the
blockade of in vivo viral propagation and even the
elimination of the virus. In particular, chimeric proteins,
which combine the nucleic acid-binding properties of the
small basic protein, protamine, with the specific ligand-
recognition properties of antibodies, have been engineered
to deliver nucleic acid drugs to HIV-infected cells, HER2
over-expressing cancers (Song et al. 2005), activated LFA-
1-expressing cells (Peer et al. 2007), and HBV-infected
cells (Wen et al. 2007a, b) in cell culture and animal
models. Antibody fragments fused to lipids also have been
used for effective retargeting of liposome-encapsulated
DNAs in cancer therapy (Pirollo et al. 2006, 2007; Brignole
et al. 2004). Taken together, these results indicate the
potential utility of antibody-targeted system for intracellular
trafficking of innovative therapeutic agents.
Hantavirus infection is mediated by the interaction of
viral surface GPs with integrin αvβ3 expressed on the host
cell surface and subsequent endocytosis (Cheresh 1987;
Hynes 1992). Hantavirus GPs include two transmembrane
proteins, G1 and G2, which result from posttranslational
cleavage of a single glycoprotein precursor and form
heterodimers in the endoplasmic reticulum during the
intracellular assembly of virus particles (Antic et al.
1992). Both G1 and G2 are normally located on the surface
and in the cytoplasm of virus-infected cells (Ogino et al.
2004). Featured by the surface expression of these GPs,
Hantavirus-infected cells could be targeted by therapeutics
containing the corresponding antibodies.
Engineered antibody fragments such as Fabs and scFvs,
which have a lower molecular weight while possessing the
affinity to the antigen, have been widely used in targeted
therapy and drugs delivery. The prokaryotic E. coli
expression system, characterized by easy genetic manipu-
lation and scale-up, and relatively short duration between
transformation and protein purification, is among the most
popular host for recombinant protein production (Arbabi-
Ghahroudi et al. 2005). In the cytoplasm of E. coli,i ti s
preferable to express antibody fragments in soluble and
active form, which can be achieved by one of the following
fusion protein strategies: (1) fusion to a polypeptide that is
highly soluble and (2) fusion to an enzyme that catalyzes
disulfide bond formation. The soluble fraction of fusion
protein allows disulfide bond formation and proper folding
of the native structure in the cytoplasm and increases the
possibility of obtaining soluble proteins with preserved
biological activity. Fusion thioredoxin to target protein has
been widely used to avoid inclusion body formation and
obtain active proteins (LaVallie and McCoy 1995; Wen et
al. 2007a, b; Moura-da-Silva et al. 1999; Wu et al. 2003). In
this study, the scFv3G1 against HTNV GP was expressed
by E. coli as a soluble fusion protein and was purified using
immobilized metal affinity chromatograph. The purified
scFv was proven active and showed specific binding to
HTNV GP antigen and then could be internalized into
HTNV-infected cells.
Application of targeted and intracellular delivery of effector
moieties requires antibodies capable of internalization, i.e., a
receptor-mediated endocytosis via a variety of clathrin-
dependent and clathrin-independent endocytic pathways. Our
results revealed that the recombinant HTNV GP antibody,
scFv3G1, can be internalized following antigen engagement
primarily through a clathrin-dependent endocytic pathway
similar to that observed with transferrin. Similar clathrin-
dependent internalization has been reported for the scFv
against HBV antigen (Wen et al. 2007a, b). In the clathrin-
dependent endocytotic pathway, internalized molecules are
delivered to the early endosome and then trafficked to the late
endosome–lysosome pathway (Mellman 1996;S o r k i na n d
Von Zastrow 2002). Therefore, the internalization character-
istics of the scFv3G1 were sufficient for the intracellular
delivery of therapeutic agents, which thus may be released to
the endolysosomal compartment, followed by rapid perme-
ation into the cytosol and nucleus. The successful generation
and purification of the Hantavirus glycoprotein antibody,
scFv3G1, together with the demonstration that it can be
internalized into HTNV-infected cells, suggests potential
application of this recombinant antibody in targeted and
intracellular delivery of effector moieties against HTNV
infection.
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